All content for iMedicus Cardiology is the property of imedicuscardiology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Current Dyslipidemia Management: What do the 2021 CCS Guidelines Say?
iMedicus Cardiology
16 minutes 8 seconds
4 years ago
Current Dyslipidemia Management: What do the 2021 CCS Guidelines Say?
Welcome to the podcast series CAN-R3: Canadian Initiative to Reduce Residual Risk – Game Changers in Dyslipidemia Management. In this series, Canadian experts discuss the importance and challenges of reducing LDL-C in patients with established ASCVD, recommendations from the 2021 Canadian Cardiovascular Society Guidelines, and evidence around statins efficacy and adherence in different patient populations. Visit iMedicus.ca/Dyslipidemia to watch the Section 1 accredited webinars.
In this first episode, Dr. Judy Luu and Dr. Shaun Goodman exchange on the different contributors to residual risk, the role of LDL-C in atherosclerosis, the importance of reducing LDL-C as low as possible, identifying patients who benefit the most from intensification therapy beyond statins, and the shift to LDL-C thresholds as opposed to treatment targets.
